Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
94.04 USD | +2.60% | +6.13% | +50.13% |
04-18 | Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing | MT |
04-18 | Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+50.13% | 11.2B | C- | ||
-14.58% | 84.68B | B- | ||
+15.05% | 81.12B | C+ | ||
+10.49% | 29.59B | C+ | ||
-10.17% | 16.73B | B | ||
-1.39% | 16.36B | A- | ||
-31.58% | 11.77B | - | - | |
+1.82% | 11.72B | A- | ||
+31.86% | 11.71B | B- | ||
-0.47% | 11.66B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NTRA Stock
- Ratings Natera, Inc.